Costs of intravenous immunoglobulin therapy in patients with unconfirmed parvovirus b19 pure red cell aplasia

Clin Infect Dis. 2015 Feb 1;60(3):488. doi: 10.1093/cid/ciu828. Epub 2014 Oct 21.

Authors

Luc Mouthon¹, Morgane Michel², Coralie Gandré³, Catherine Montagnier-Petrissans⁴, Karine Chevreul³

Affiliations

¹ Faculty of Medicine, Université Paris Descartes and Department of Internal Medicine, Cochin hospital, Assistance Publique-Hôpitaux de Paris (AP-HP) Commission for the Adequate Prescription of Drugs, AP-HP.
² URC Eco Ile de France, AP-HP.
³ URC Eco Ile de France, AP-HP Université Paris Diderot, Sorbonne Paris Cité, ECEVE, UMRS 1123 Inserm, ECEVE, U1123, Paris, France.
⁴ Commission for the Adequate Prescription of Drugs, AP-HP.

PMID: 25336624
DOI: 10.1093/cid/ciu828

No abstract available

Publication types

Letter
Comment

MeSH terms

Female
Humans
Immunoglobulins, Intravenous / therapeutic use*
Male
Parvoviridae Infections / complications*
Parvoviridae Infections / therapy*
Parvovirus B19, Human / isolation & purification*
Red-Cell Aplasia, Pure / therapy*

Substances

Immunoglobulins, Intravenous